To progress a lead compound from the S07 series into clinical development as a potential new treatment for leishmaniasis
current phase of drug development
updated 15 Feb 2023
This project originated from DNDi’s successful NTD Drug Discovery Booster programme. As a result of further collaboration with Takeda Pharmaceutical Company Limited to identify and advance novel compounds against visceral leishmaniasis, the S07 lead chemical series of compounds showed promising efficacy and safety profiles. DNDi and Takeda are collaborating on medicinal chemistry optimization of the S07 leads that have been identified, with the aim of progressing at least one optimized lead through to a pre-clinical candidate compound for visceral leishmaniasis, with funding support from Japan’s Global Health Innovative Technology Fund (GHIT Fund).
News & resources
- 6 October 2021 - Projets de l’année 2021 de DNDi : des partenaires et des collègues récompensés pour le travail accompli dans la mise au point de nouveaux traitements de la leishmaniose viscérale et de la maladie du sommeil
- 6 October 2021 - DNDi 2021 Projects of the Year recognize partners and colleagues for their work in developing new treatments for visceral leishmaniasis and sleeping sickness
Get our latest news, personal stories, research articles, and job opportunities.